Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

The FDA has approved Yeztugo for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35kg.

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...